Pharma Pioneer

Vividion Initiates Phase I Trial for Oral STAT3 Inhibitor in Advanced Tumors

29 May 2024
2 min read

Vividion Therapeutics, a subsidiary of Bayer AG, has commenced a Phase I clinical trial for VVD-130850, an oral STAT3 inhibitor intended to treat advanced solid and hematologic tumors, both as a standalone treatment and in combination with checkpoint inhibitors. The compound is unique in that it modulates STAT3 function and the expression of its target genes without altering the protein's levels. This development is a significant achievement for Vividion's chemoproteomics platform, which is focused on identifying and developing therapies for traditionally undruggable targets in cancer and immune disorders.
The trial will assess the safety, tolerability, and preliminary efficacy of VVD-130850, as well as its pharmacokinetic and pharmacodynamic properties. The drug is designed to bind to a novel allosteric site on STAT3, inhibiting its DNA binding and downstream gene expression, which are implicated in cancer cell survival and growth. The STAT3 protein is a critical regulatory factor that, when hyperactivated, can contribute to tumor progression and resistance to treatment.
Vividion's chemoproteomics platform has been instrumental in advancing a pipeline of selective small molecule therapeutics aimed at high-value targets in oncology and immunology. The company's innovative approach has led to the discovery of numerous previously unknown functional sites on well-studied proteins associated with a range of diseases. Vividion's acquisition by Bayer in August 2021 has allowed it to maintain its entrepreneurial spirit while benefiting from Bayer's expertise in drug development and global resources.
Bayer is a global life sciences company with a focus on healthcare and nutrition, dedicated to sustainable development and positive societal impact. In fiscal 2022, the company had sales of €50.7 billion and employed approximately 101,000 people worldwide. The company's commitment to innovation and growth is evident in its R&D investments, which amounted to €6.2 billion before special items.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Thermosome Advances to Higher Dosage in THE001 Phase I Clinical Trial
Pharma Pioneer
2 min read
Thermosome Advances to Higher Dosage in THE001 Phase I Clinical Trial
29 May 2024
Thermosome has received approval from the Data Safety Monitoring Board (DSMB) to continue with the planned dosage increase in its Phase I clinical trial for THE001.
Read →
AgenT-797 Demonstrates Potential in Treating Severe ARDS, Study in Nature Communications Reveals
Pharma Pioneer
3 min read
AgenT-797 Demonstrates Potential in Treating Severe ARDS, Study in Nature Communications Reveals
29 May 2024
MiNK Therapeutics's primary product, AGENT-797, is currently undergoing multiple Phase 1 clinical trials, with anticipated results to be released later this year.
Read →
First Patient Dosed in Prokarium's PARADIGM-1 NMIBC Trial
Pharma Pioneer
2 min read
First Patient Dosed in Prokarium's PARADIGM-1 NMIBC Trial
29 May 2024
Prokarium has initiated a Phase I/Ib clinical trial, known as PARADIGM-1, for non-muscle invasive bladder cancer (NMIBC) patients.
Read →
REGENXBIO Completes Cohort 2 Enrollment and Reports Positive Interim AFFINITY DUCHENNE® Trial Data
Pharma Pioneer
3 min read
REGENXBIO Completes Cohort 2 Enrollment and Reports Positive Interim AFFINITY DUCHENNE® Trial Data
29 May 2024
REGENXBIO has successfully completed patient recruitment for the second group in the Phase I/II AFFINITY DUCHENNE® clinical trial, which is examining the safety and effectiveness of RGX-202.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.